Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential.

Patents show all


SEC Filings show all


Contact Information

200 Cambridge Park Drive, Suite 3100
Cambridge, MA 02140
United States

(617) 843-5032


    Total FundingEmployeesLast Funding DateStatus

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2018-03-08$86,000,000Corporate Round
    2017-03-15$15,000,000Debt FinancingSquare 1 Bank
    2015-06-11$65,000,000Series BNew Leaf Venture PartnersBrace Pharma, Novo Holdings, Cowen Group, Jennison Associates, F-Prime Capital Partners, Sanofi-Genzyme BioVentures, Atlas Venture, Seattle Genetics, Sectoral Asset Management, Wellington Management, Sabby Management
    2014-10-21$12,300,000Series AF-Prime Capital Partners, Atlas VentureSanofi-Genzyme BioVentures

    SEC Form D Funding Events


    Key Executives

    • Charles Wilson
      Executive Officer, Director
    • Ben Auspitz
    • Bruce Booth